statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

GRI Bio sees cash runway into 3Q24

GRI Bio reports 2023 EPS ($28.25) vs. ($24.95) last year

Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024...

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Live webcast on Wednesday, April 3rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ( GRI Bio or the Company ), a biotechnology company advancing...

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases Ongoing efforts to build a robust global patent estate for a...

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ( IPF ) with interim data expected H1 2024 and...

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

GRI Bio, Inc. (NASDAQ:GRI  Get Free Report) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 18,600 shares, a...

Short Interest in GRI Bio, Inc. (NASDAQ:GRI) Declines By 64.7%

GRI Bio (NASDAQ:GRI  Get Free Report) and BioMarin Pharmaceutical (NASDAQ:BMRN  Get Free Report) are both medical companies, but which is the better business? We will compare the two...

GRI Bio (NASDAQ:GRI) versus BioMarin Pharmaceutical (NASDAQ:BMRN) Head to Head Comparison

GRI Bio prices 5M shares at $1.10 in public offering...

GRI Bio prices 5M shares at $1.10 in public offering

LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ( GRI Bio or the Company ), a biotechnology company advancing an innovative pipeline of Natural Killer T ( NKT ) cell...

GRI Bio Announces Pricing of $5.5 Million Public Offering

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

Volume	100,200.00
52-Wk High	$62.23
52-Wk Low	$0.421

GRI GRI Bio Inc

About

Feed

News

Fundamentals